The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules.The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules.Aduhelm (Drug), Alzheimer’s Disease, Drugs (Pharmaceuticals), Inspectors General, Biogen Inc, Food and Drug Administration, Woodcock, JanetRead More
